Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Mar 25, 2010

Premium

Title: Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding RNAs

Patent Number: 7,683,036

Filed: July 30, 2004

Lead Inventor: Christine Esau, Regulus Therapeutics

The patent, its abstract states, claims "compounds, compositions, and methods … for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs, as well as downstream targets of these RNAs, and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided."


Titles: RNA Interference-Mediated Inhibition of Interleukin and Interleukin Receptor Gene Expression Using Short Interfering Nucleic Acid

Patent Numbers: 7,683,165; 7,683,166

Filed: Sept. 3 & 4, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating interleukin and/or interleukin receptor gene expression using short interfering nucleic acid molecules," the patents' abstracts state. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of interleukin and/or interleukin receptor gene expression and/or activity by RNA interference using small nucleic acid molecules … and methods used to modulate the expression of interleukin and/or interleukin receptor genes."


Title: Apoptotic Cell-Mediated Transfection of Mammalian Cells with Interfering RNA

Application Number: 20100068813

Filed: Sept. 28, 2007 PCT Filed: Sept. 28, 2007

Lead Inventor: Fengchun Li, Loma Linda University

The patent application, its abstract states, claims "mammalian host cells for use in a cell-mediated transfection process [that] contain an RNAi molecule and an expression vector for a pro-apoptotic protein. The method includes inducing apoptotic cell death in mammalian cells that contain an RNAi molecule capable of down-regulating a chosen target gene. Living cells expressing the target gene are then exposed to the [apoptotic cells, which are] processed by the living cells, and the RNAi molecule in the [apoptotic cells] down-regulates the expression of the target gene in living cells."


Title: Multi-microRNA Methods and Compositions

Application Number: 20100068814

Filed: Nov. 28, 2007 PCT Filed: Nov. 28, 2007

Lead Inventor: Liang Zhu, Albert Einstein College of Medicine

The invention, the patent application's abstract states, relates to "DNAs comprising a polynucleotide that encodes at least a first modified miR-30 precursor and a second modified miR-30 precursor. Also provided are [DNA vectors], where the vector can replicate in a host cell. Additionally, specific lentiviral vectors comprising the above-described DNA are provided, as are methods of inhibiting expression of a target gene in a eukaryotic cell."


Title: siRNA Targeting Proto-Oncogene MET

Application Number: 20100069261

Filed: Nov. 2, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for proto-oncogene MET."


Title: Compositions and Methods for Inhibiting Expression of Factor V Leiden Mutant Gene

Application Number: 20100069461

Filed: Nov. 7, 2006 PCT Filed: Nov. 7, 2006

Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the Factor V Leiden mutant gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene," the patent application's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell."


Title: Compositions and Methods for Modulating Activity of Capped Small RNAs

Application Number: 20100069464

Filed: Aug. 21, 2009

Lead Inventor: Mark Kay, Stanford University

The patent application, its abstract states, claims "compositions and methods for modulating transcription by RNA polymerases."


Title: Compositions and Methods for the Specific Inhibition of Gene Expression by Double-Stranded RNA

Application Number: 20100069465

Filed: Aug. 27, 2009

Lead Inventor: John Rossi, City of Hope (Integrated DNA Technologies)

"The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene," the patent application's abstract states. "More particularly, the invention is directed to compositions that contain double-stranded RNA, and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery."


Title: Novel Compositions of Chemically Modified Small Interfering RNA

Application Number: 20100069620

Filed: Jan. 23, 2007 PCT Filed: Jan. 23, 2007

Inventor: Gerald Zon, RXi Pharmaceuticals

The invention "is directed to compositions comprising chemically modified siRNA that have high specificity by virtue of no or insignificant off-target activity of the sense strand; no or insignificant induction of IFN-like responses; high potency to offset oligonucleotide manufacturing costs; favorable manufacturing chemistry; and effective means of intracellular delivery both in vitro, during target validation and model studies, and in vivo, during animal model studies and clinical trials in humans," the patent application's abstract states.


Title: siRNA Targeting Amyloid Beta Precursor Protein

Application Number: 20100069622

Filed: Nov. 4, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for APP."

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.